

EQA round: CSFB2/23 - Cerebrospinal Fluid Analysis

Deadline: 27.11.2023

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

RoM = robust average	AV = assigned value	D _{max} = acceptable difference
SD = standard deviation	CVP = consensus of all participants	LL = lower limit
CV = coefficient of variation	U _{AV} = expanded uncertainty of the assigned value (k = 2)	UL = upper limit
N _{tot} = total number of the results		N _{eva} = number of the results assessed
N _{out} = number of the results removed before calculation		N _{suc} = number of successful results
		S _{rel} = relative success

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(333) Albumin	[mg/L]				75							75	74	99	
Sample A		444	31	7	75		CVP	444	8,7	23%	341	547	75	74	99
(1) Abbott		464	10	2,2	8	0							8		
(58) Beckman Coulter (AU)		439	16	3,6	9	0							9		
(60) Roche		428	14	3,2	23	0							23		
(149) Siemens (Dade, BN, Dimension)		476	20	4,2	12	0							12		
(162) Siemens (Atellica)		423	93	22	8	0							8		
(179) Siemens		443	26	5,9	7	0							7		
Other					8	0							8		
								3x 12, 3x 91, 1x 152, 1x 178							
Sample B		179	12	6,5	75		CVP	179	3,3	23%	137	221	75	74	99
(1) Abbott		182	14	7,5	8	0							8		
(58) Beckman Coulter (AU)		179	7,1	4	9	0							9		
(60) Roche		175	7,1	4,1	23	0							23		
(149) Siemens (Dade, BN, Dimension)		191	7,6	4	12	0							12		
(162) Siemens (Atellica)		172	32	19	8	0							8		
(179) Siemens		180	8,2	4,5	7	0							7		
Other					8	0							8		
								3x 12, 3x 91, 1x 152, 1x 178							
(330) Total protein	[mg/L]				98								98	91	93
Sample A		693	60	8,7	98		CVP	693	15	27%	505	881	98	95	97
(1) Abbott		674	20	2,9	12	0							12		
(58) Beckman Coulter (AU)		761	15	1,9	15	0							15		
(60) Roche		651	23	3,6	42	1							42		
(162) Siemens (Atellica)		759	10	1,4	9	0							9		
Other					20	0							20		
								2x 46, 1x 75, 3x 77, 1x 85, 1x 115, 3x 149, 1x 158, 1x 166, 2x 178, 4x 179, 1x 998							
Sample B		297	48	16	98		CVP	297	12	32%	201	393	98	93	95
(1) Abbott		273	17	6,1	12	0							12		
(58) Beckman Coulter (AU)		337	11	3,4	15	0							15		
(60) Roche		268	12	4,5	42	1							42		
(162) Siemens (Atellica)		369	13	3,4	9	0							9		
Other					20	0							20		
								2x 46, 1x 75, 3x 77, 1x 85, 1x 115, 3x 149, 1x 158, 1x 166, 2x 178, 4x 179, 1x 998							
(331) Glucose	[mmol/L]				98								98	98	100
Sample A		1,79	0,043	2,4	98		CVP	1,79	0,011	18%	1,46	2,12	98	98	100
(1) Abbott		1,77	0,059	3,3	10	0							10		
(46) Erba Lachema		1,75	0,059	3,4	6	0							6		
(58) Beckman Coulter (AU)		1,79	0,078	4,4	17	0							17		
(60) Roche		1,78	0,029	1,6	41	0							41		
(162) Siemens (Atellica)		1,82	0,049	2,7	10	0							10		
Other					14	0							14		
								1x 49, 1x 75, 3x 149, 2x 158, 1x 178, 4x 179, 1x 187, 1x 188							
Sample B		3,12	0,072	2,3	98		CVP	3,12	0,018	18%	2,55	3,69	98	98	100
(1) Abbott		3,1	0,083	2,7	10	0							10		
(46) Erba Lachema		3,13	0,12	3,8	6	0							6		
(58) Beckman Coulter (AU)		3,1	0,081	2,6	17	0							17		
(60) Roche		3,11	0,061	1,9	41	0							41		
(162) Siemens (Atellica)		3,16	0,056	1,8	10	0							10		
Other					14	0							14		
								1x 49, 1x 75, 3x 149, 2x 158, 1x 178, 4x 179, 1x 187, 1x 188							
(335) IgA	[mg/L]				21								21	21	100
Sample A		11,3	1,2	10	21		CVP	11,3	0,63	32%	7,68	15	21	21	100
(149) Siemens (Dade, BN, Dimension)		11	0,69	6,3	10	0							10		
Other					11	0							11		
								3x 12, 3x 91, 2x 162, 3x 179							
Sample B		6,43	0,62	9,7	21		CVP	6,43	0,33	32%	4,37	8,49	21	21	100
(149) Siemens (Dade, BN, Dimension)		6,3	0,49	7,8	10	0							10		
Other					11	0							11		
								3x 12, 3x 91, 2x 162, 3x 179							
(334) IgG	[mg/L]				43								43	42	98
Sample A		88,8	7,5	8,4	43		CVP	88,8	2,8	24%	67,4	111	43	43	100
(60) Roche		84,3	3,6	4,3	14	0							14		

EQA round: CSFB2/23 - Cerebrospinal Fluid Analysis

Deadline: 27.11.2023

Setup: groups - R (manufacturer of kit); minimal size of the groups n = 5

Test Sample Group	[unit]	RoM	SD	CV [%]	N _{tot}	N _{out}	Comparability					N _{eva}	N _{suc}	S _{rel} [%]	
							AV	U _{AV}	D _{max}	LL	UL				
(91) Binding Site		86	2,1	2,5	6	0							6		
(149) Siemens (Dade, BN, Dimension)		91,4	7,1	7,8	12	0							12		
Other					11	0							11		
							3x 12, 1x 58, 3x 162, 4x 179								
Sample B		34,3	2	5,8	43		CVP	34,3	0,75	24%	26	42,6	43	42	98
(60) Roche		32,6	2	6,2	14	0							14		
(91) Binding Site		36,2	4,7	13	6	0							6		
(149) Siemens (Dade, BN, Dimension)		34,7	1,3	3,8	12	0							12		
Other					11	0							11		
							3x 12, 1x 58, 3x 162, 4x 179								
(336) IgM	[mg/L]				29								29	28	97
Sample A		56,9	5,1	9	29		CVP	56,9	2,3	31%	39,2	74,6	29	28	97
(91) Binding Site		57,2	8,7	15	5	0							5		
(149) Siemens (Dade, BN, Dimension)		57,9	3,7	6,4	12	0							12		
Other					12	0							12		
							3x 12, 4x 60, 2x 162, 3x 179								
Sample B		2,52	0,26	10	29		CVP	2,52	0,12	31%	1,73	3,31	29	29	100
(91) Binding Site		2,51	0,31	12	5	0							5		
(149) Siemens (Dade, BN, Dimension)		2,61	0,091	3,5	12	0							12		
Other					12	0							12		
							3x 12, 4x 60, 2x 162, 3x 179								
(338) Lactate	[mmol/L]				95								95	92	97
Sample A		7,66	0,29	3,8	95		CVP	7,66	0,073	20%	6,12	9,2	95	93	98
(1) Abbott		7,8	0,91	12	8	0							8		
(58) Beckman Coulter (AU)		7,69	0,21	2,7	15	0							15		
(60) Roche		7,69	0,18	2,4	44	0							44		
(162) Siemens (Atellica)		7,41	0,39	5,3	10	0							10		
Other					18	0							18		
							3x 49, 1x 61, 2x 75, 1x 116, 3x 149, 2x 178, 4x 179, 2x 188								
Sample B		1,99	0,094	4,7	95		CVP	1,99	0,024	20%	1,59	2,39	95	94	99
(1) Abbott		2,06	0,067	3,2	8	0							8		
(58) Beckman Coulter (AU)		1,95	0,042	2,2	15	0							15		
(60) Roche		2,03	0,06	3	44	0							44		
(162) Siemens (Atellica)		1,84	0,15	8,2	10	0							10		
Other					18	0							18		
							3x 49, 1x 61, 2x 75, 1x 116, 3x 149, 2x 178, 4x 179, 2x 188								